Your session is about to expire
← Back to Search
Poziotinib for Non-Small Cell Lung Cancer (PINNACLE Trial)
PINNACLE Trial Summary
This trial will compare the effects of two drugs on lung cancer patients with HER2 exon 20 mutations.
- Non-Small Cell Lung Cancer
PINNACLE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 2 trial • 67 Patients • NCT02659514PINNACLE Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many individuals have signed up to participate in this research project?
"Yes. The most recent information available on clinicaltrials.gov indicates that this trial is still recruiting patients. This study was first posted on May 12th, 2022 and received its latest update June 10th of the same year. There is space for 268 participants at a single location."
Are investigators looking for more participants?
"Yes, this trial is currently open for enrolment according to the website clinicaltrials.gov. The listing was first put up on May 12th, 2022 and edited most recently on June 10th of the same year."
Do we know of any adverse effects to taking Poziotinib?
"Poziotinib's safety is estimated to be a 3. This judgement comes from the fact that Poziotinib is in Phase 3 trials, which suggests that not only does some data support efficacy, but multiple rounds of testing have been conducted to support safety."
Share this study with friends
Copy Link
Messenger